Correlia Biosystems
Operating Status: Closed
Correlia Biosystems: Innovating microscale tools for rapid biomolecule quantification.
Correlia Biosystems: Innovating microscale tools for rapid biomolecule quantification.
Correlia Biosystems, a UC Berkeley spinoff based in Berkeley, CA, is dedicated to revolutionizing biomolecule quantification through innovative microscale tools. Their core mission is to provide next-gen blood testing that delivers 1000x more data to pharmaceutical companies. The company's flagship product, "SimpleScan," enables rapid and dynamic monitoring of protein expression profiles from just one microliter of sample. This technology has applications in next-gen proteomics and point-of-care diagnostics, aiming to open new biological research avenues.
Notable figures affiliated with Correlia Biosystems include experts from UC Berkeley, contributing to its strong academic foundation. The company has attracted significant interest from investors focused on cutting-edge biotech innovations. Key achievements include the successful development and implementation of the SimpleScan technology, which has garnered attention for its efficiency and potential impact on pharmaceutical research and diagnostics. Overall, Correlia Biosystems is poised to make substantial contributions to data-driven biology and personalized medicine.
Companies similar to Correlia Biosystems include Probius, Signatur Biosciences, Spear Bio and Hermes Life Sciences.
Correlia Biosystems was founded in 2013.
Correlia Biosystems' headquarters is located in Berkeley, CA, US.
Correlia Biosystems' most recent funding round was for $9.6M (USD) in October 2020.
As of Oct 16, 2020, Correlia Biosystems has disclosed funding of $10.7M (USD). Undisclosed round amounts are excluded.
Hermes Life Sciences
